Immunization of mice with antibiotic-treated Escherichia coli results in enhanced protection against challenge with homologous and heterologous bacteria.
The murine immune response to Escherichia coli exposed to subminimal inhibitory concentrations of four antibiotics was investigated. Groups of mice were injected for 8 weeks with formalin-killed bacteria and subsequently challenged with 10 x LD50 of viable E. coli. Mice receiving saline only (controls) died within 24 h. The mortality of mice immunized with ciprofloxacin-treated E. coli was significantly lower than that of mice immunized with E. coli untreated or treated with other antibiotics. Sera from mice immunized with ciprofloxacin-treated bacteria showed better bacteriostatic capacity and enhanced production of antibodies that bound to homologous and heterologous lipopolysaccharide isolated from several smooth and rough gram-negative strains. The better protection observed in mice immunized with ciprofloxacin-treated E. coli was probably due to an enhanced production of antibodies to epitopes on lipopolysaccharide that became better exposed and so more accessible after treatment with ciprofloxacin.
Eijkman-Winkler Laboratory for Medical Microbiology, University Hospital of Utrecht, Netherlands.
G
G
Raponi
N
N
Keller
B P
BP
Overbeek
M
M
Rozenberg-Arska
R
R
Torensma
J
J
Verhoef
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001398:Aztreonam / Q000031:analogs & derivatives / Q000494:pharmacology; D001770:Blood Bactericidal Activity; D002443:Ceftriaxone / Q000494:pharmacology; D002939:Ciprofloxacin / Q000494:pharmacology; D003165:Complement System Proteins / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D000939:Epitopes / Q000276:immunology; D004926:Escherichia coli / Q000187:drug effects / Q000276:immunology*; D004927:Escherichia coli Infections / Q000517:prevention & control*; D005260:Female; D007114:Immunization; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D008070:Lipopolysaccharides / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D009428:Netilmicin / Q000494:pharmacology; D009895:Opsonin Proteins / Q000276:immunology; D010587:Phagocytosis
D000900:Anti-Bacterial Agents; D000939:Epitopes; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D008070:Lipopolysaccharides; D009895:Opsonin Proteins; C044145:carumonam; D009428:Netilmicin; D002939:Ciprofloxacin; D002443:Ceftriaxone; D003165:Complement System Proteins; D001398:Aztreonam